Animal and organoid models show that the GLS inhibitor CB-839 exerts enhanced antitumor effects in KRAS-mutant CRC, particularly when combined with energy metabolism inhibitors such as metformin (39, 40). Here, GLS is linked to colorectal carcinoma.